1. Home
  2. PED vs VTVT Comparison

PED vs VTVT Comparison

Compare PED & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pedevco Corp.

PED

Pedevco Corp.

HOLD

Current Price

$13.56

Market Cap

152.8M

Sector

Energy

ML Signal

HOLD

Logo vTv Therapeutics Inc.

VTVT

vTv Therapeutics Inc.

HOLD

Current Price

$34.66

Market Cap

148.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PED
VTVT
Founded
N/A
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
152.8M
148.7M
IPO Year
2012
2015

Fundamental Metrics

Financial Performance
Metric
PED
VTVT
Price
$13.56
$34.66
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
5
Target Price
$30.00
$53.00
AVG Volume (30 Days)
22.2K
85.2K
Earning Date
05-15-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$45,751,000.00
N/A
Revenue This Year
$171.75
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
15.67
N/A
52 Week Low
$0.43
$15.79
52 Week High
$18.89
$44.00

Technical Indicators

Market Signals
Indicator
PED
VTVT
Relative Strength Index (RSI) 64.89 54.42
Support Level $12.89 $29.66
Resistance Level $13.92 $34.11
Average True Range (ATR) 0.72 2.00
MACD 0.35 0.15
Stochastic Oscillator 97.69 61.48

Price Performance

Historical Comparison
PED
VTVT

About PED Pedevco Corp.

PEDEVCO Corp is an oil and gas company focused on oil and natural gas development, exploration, and production. The company focuses on legacy properties with a long production history, well-defined geology, and existing infrastructure that can be leveraged when applying modern field management technologies. The current properties in the Denver-Julesberg Basin (D-J Basin) in Colorado and Wyoming, the Powder River Basin (PRB) in Wyoming, and the San Andres formation of the Permian Basin situated in West Texas and eastern New Mexico (the Permian Basin).

About VTVT vTv Therapeutics Inc.

vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.

Share on Social Networks: